Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Non-Current Liabilities (2016 - 2025)

Arcadia Biosciences' Total Non-Current Liabilities history spans 12 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 54.55% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, down 54.55%, while the annual FY2025 figure was $2.4 million, 54.55% down from the prior year.
  • Total Non-Current Liabilities reached $2.4 million in Q4 2025 per RKDA's latest filing, down from $3.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $26.0 million in Q2 2021 to a low of $2.4 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $8.0 million, with a median of $6.0 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 75.98% in 2022, then soared 79.78% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $10.7 million in 2021, then tumbled by 43.47% to $6.0 million in 2022, then dropped by 16.94% to $5.0 million in 2023, then rose by 5.84% to $5.3 million in 2024, then crashed by 54.55% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Total Non-Current Liabilities are $2.4 million (Q4 2025), $3.1 million (Q3 2025), and $3.3 million (Q2 2025).